These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 38643482)

  • 81. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer.
    Xiong S; Song K; Xiang H; Luo G
    Eur J Med Chem; 2024 Apr; 270():116393. PubMed ID: 38588626
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Repression of ESR1 transcription by MYOD potentiates letrozole-resistance in ERα-positive breast cancer cells.
    Zhang Q; Liu XY; Li S; Zhao Z; Li J; Cui MK; Wang EH
    Biochem Biophys Res Commun; 2017 Oct; 492(3):425-433. PubMed ID: 28842253
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Overview of the therapeutic strategies for ER positive breast cancer.
    Blakely B; Shin S; Jin K
    Biochem Pharmacol; 2023 Jun; 212():115552. PubMed ID: 37068524
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Current research topics in endocrine therapy for breast cancer.
    Yamashita H
    Int J Clin Oncol; 2008 Oct; 13(5):380-3. PubMed ID: 18946747
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα
    Puyang X; Furman C; Zheng GZ; Wu ZJ; Banka D; Aithal K; Agoulnik S; Bolduc DM; Buonamici S; Caleb B; Das S; Eckley S; Fekkes P; Hao MH; Hart A; Houtman R; Irwin S; Joshi JJ; Karr C; Kim A; Kumar N; Kumar P; Kuznetsov G; Lai WG; Larsen N; Mackenzie C; Martin LA; Melchers D; Moriarty A; Nguyen TV; Norris J; O'Shea M; Pancholi S; Prajapati S; Rajagopalan S; Reynolds DJ; Rimkunas V; Rioux N; Ribas R; Siu A; Sivakumar S; Subramanian V; Thomas M; Vaillancourt FH; Wang J; Wardell S; Wick MJ; Yao S; Yu L; Warmuth M; Smith PG; Zhu P; Korpal M
    Cancer Discov; 2018 Sep; 8(9):1176-1193. PubMed ID: 29991605
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Arsenic‑induced BRCA1 CpG promoter methylation is associated with the downregulation of ERα and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts.
    Selmin OI; Donovan MG; Skovan B; Paine-Murieta GD; Romagnolo DF
    Int J Oncol; 2019 Mar; 54(3):869-878. PubMed ID: 30664189
    [TBL] [Abstract][Full Text] [Related]  

  • 87. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
    Herzog SK; Fuqua SAW
    Br J Cancer; 2022 Feb; 126(2):174-186. PubMed ID: 34621045
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Liver tropism of ER mutant breast cancer is characterized by unique molecular changes and immune infiltration.
    Wu Y; Li Z; Lee AV; Oesterreich S; Luo B
    Breast Cancer Res Treat; 2024 Jun; 205(2):371-386. PubMed ID: 38427312
    [TBL] [Abstract][Full Text] [Related]  

  • 89. High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy.
    Lupini L; Moretti A; Bassi C; Schirone A; Pedriali M; Querzoli P; Roncarati R; Frassoldati A; Negrini M
    Sci Rep; 2018 Mar; 8(1):4371. PubMed ID: 29531247
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Intratumoural inflammation and endocrine resistance in breast cancer.
    Murray JI; West NR; Murphy LC; Watson PH
    Endocr Relat Cancer; 2015 Feb; 22(1):R51-67. PubMed ID: 25404688
    [TBL] [Abstract][Full Text] [Related]  

  • 91. MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer.
    Luan R; He M; Li H; Bai Y; Wang A; Sun G; Zhou B; Wang M; Wang C; Wang S; Zeng K; Feng J; Lin L; Wei Y; Kato S; Zhang Q; Zhao Y
    EMBO Mol Med; 2024 Jan; 16(1):10-39. PubMed ID: 38177530
    [TBL] [Abstract][Full Text] [Related]  

  • 92. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
    Toy W; Shen Y; Won H; Green B; Sakr RA; Will M; Li Z; Gala K; Fanning S; King TA; Hudis C; Chen D; Taran T; Hortobagyi G; Greene G; Berger M; Baselga J; Chandarlapaty S
    Nat Genet; 2013 Dec; 45(12):1439-45. PubMed ID: 24185512
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
    Tomita S; Zhang Z; Nakano M; Ibusuki M; Kawazoe T; Yamamoto Y; Iwase H
    Cancer Sci; 2009 Jun; 100(6):1012-7. PubMed ID: 19320640
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
    Sundaresan TK; Dubash TD; Zheng Z; Bardia A; Wittner BS; Aceto N; Silva EJ; Fox DB; Liebers M; Kapur R; Iafrate J; Toner M; Maheswaran S; Haber DA
    Breast Cancer Res Treat; 2021 Jul; 188(1):43-52. PubMed ID: 34101078
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Endocrine Resistance in Breast Cancer: The Role of Estrogen Receptor Stability.
    Jeffreys SA; Powter B; Balakrishnar B; Mok K; Soon P; Franken A; Neubauer H; de Souza P; Becker TM
    Cells; 2020 Sep; 9(9):. PubMed ID: 32932819
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Genomic index of sensitivity to endocrine therapy for breast cancer.
    Symmans WF; Hatzis C; Sotiriou C; Andre F; Peintinger F; Regitnig P; Daxenbichler G; Desmedt C; Domont J; Marth C; Delaloge S; Bauernhofer T; Valero V; Booser DJ; Hortobagyi GN; Pusztai L
    J Clin Oncol; 2010 Sep; 28(27):4111-9. PubMed ID: 20697068
    [TBL] [Abstract][Full Text] [Related]  

  • 97. MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer.
    Cochrane DR; Cittelly DM; Howe EN; Spoelstra NS; McKinsey EL; LaPara K; Elias A; Yee D; Richer JK
    Horm Cancer; 2010 Dec; 1(6):306-19. PubMed ID: 21761362
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A functional interplay between ZNF217 and estrogen receptor alpha exists in luminal breast cancers.
    Nguyen NT; Vendrell JA; Poulard C; Győrffy B; Goddard-Léon S; Bièche I; Corbo L; Le Romancer M; Bachelot T; Treilleux I; Cohen PA
    Mol Oncol; 2014 Dec; 8(8):1441-57. PubMed ID: 24973012
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition.
    Udden SN; Wang Q; Kumar S; Malladi VS; Wu SY; Wei S; Posner BA; Geboers S; Williams NS; Liu Y; Sharma JK; Mani RS; Malladi S; Parra K; Hofstad M; Raj GV; Larios JM; Jagsi R; Wicha MS; Park BH; Gupta GP; Chinnaiyan AM; Chiang CM; Alluri PG
    JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35881485
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.
    Yu L; Liang Y; Cao X; Wang X; Gao H; Lin SY; Schiff R; Wang XS; Li K
    Oncogene; 2017 May; 36(20):2910-2918. PubMed ID: 27893709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.